Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Alvotech - Ordinary Shares (NQ: ALVO ) 11.90 +0.55 (+4.85%) Streaming Delayed Price Updated: 4:00 PM EDT, Sep 27, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Alvotech - Ordinary Shares < Previous 1 2 3 4 5 6 Next > Earnings Scheduled For November 28, 2023 November 28, 2023 Companies Reporting Before The Bell • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.70 per share on revenue of $1.45 billion. Via Benzinga Alvotech's Earnings: A Preview November 27, 2023 Via Benzinga Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET November 21, 2023 From Alvotech Via GlobeNewswire Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab) November 14, 2023 From Alvotech Via GlobeNewswire STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara November 10, 2023 From Alvotech Via GlobeNewswire Alvotech to Present at the Jefferies 2023 London Healthcare Conference November 07, 2023 From Alvotech Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2023 October 20, 2023 Via Benzinga Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04 October 12, 2023 From Alvotech Via GlobeNewswire Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab) October 03, 2023 From Kashiv Biosciences LLC Via Business Wire Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab) October 03, 2023 From Alvotech Via GlobeNewswire Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara® September 25, 2023 From Alvotech Via GlobeNewswire Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2023 September 21, 2023 Via Benzinga Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab) September 20, 2023 From Alvotech Via GlobeNewswire Alvotech Announces Changes to the Leadership Team September 05, 2023 From Alvotech Via GlobeNewswire Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update August 30, 2023 From Alvotech Via GlobeNewswire Earnings Scheduled For August 30, 2023 August 30, 2023 Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its second quarter. Via Benzinga Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt August 29, 2023 - Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure From Alvotech Via GlobeNewswire Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET August 22, 2023 From Alvotech Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and FMC and Encourages Investors to Contact the Firm August 11, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm August 06, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm July 31, 2023 From Bragar Eagel & Squire Via GlobeNewswire Alvotech Completes $100 Million Convertible Bond Private Placement July 31, 2023 From Alvotech Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm July 26, 2023 From Bragar Eagel & Squire Via GlobeNewswire Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership July 24, 2023 From Alvotech Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm July 21, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm July 16, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm July 10, 2023 From Bragar Eagel & Squire Via GlobeNewswire Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Zai Lab, and Alvotech and Encourages Investors to Contact the Firm July 05, 2023 From Bragar Eagel & Squire Via GlobeNewswire 12 Health Care Stocks Moving In Tuesday's Pre-Market Session July 04, 2023 Via Benzinga 12 Health Care Stocks Moving In Monday's Pre-Market Session July 03, 2023 Via Benzinga < Previous 1 2 3 4 5 6 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.